Expression of Cancer/Testis genes in ductal carcinoma in situ and benign lesions of the breast

Abstract

Cancer/testis (CT) genes represent a unique class of genes, which are expressed by germ cells, normally silenced in somatic cells, but activated in various cancers. CT proteins can elicit spontaneous immune responses in cancer patients and this feature makes them attractive targets for immunotherapy-based approaches. We have previously reported that CTs are relatively commonly expressed in estrogen receptor (ER) negative, high risk carcinomas. In this study, we examined the expression of selected CT genes in ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and benign proliferative lesions of the breast. ER negative DCIS were found to be associated with significant CT gene expression together with HER2 positivity and a marked stromal immune response.

Extracted Key Phrases

4 Figures and Tables

Cite this paper

@inproceedings{Caballero2014ExpressionOC, title={Expression of Cancer/Testis genes in ductal carcinoma in situ and benign lesions of the breast}, author={Otavia L. Caballero and Sami Shousha and Qi Zhao and Andrew J. G. Simpson and Raul Charles Coombes and A. Munro Neville}, booktitle={Oncoscience}, year={2014} }